Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00441545 | Head to Head Study Against Sevelamer Hydrochloride | PHASE3 | COMPLETED | 182 | — | — | Jan 5, 2007 | Jul 31, 2008 | Jun 11, 2021 | 44 | United States, Germany +2 |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Fosrenol (Lanthanum carbonate) |
| 2 | ACTIVE_COMPARATOR | Sevelamer hydrochloride |
| Name | Type | Description |
|---|---|---|
| Fosrenol (Lanthanum Carbonate) | DRUG | The starting dose is a total daily dose of 2250mg of Fosrenol (Lanthanum carbonate) to a maximum dose of 3000mg daily. Chewable tablets will be administered orally with meals in 750mg and 1000mg strength tablets. |
| Sevelamer hydrochloride | DRUG | The starting dose is a total daily dose of 4800mg of sevelamer hydrochloride up to a maximum of 6400 mg daily. Sevelamer hydrochloride 800mg tablets, administered orally with meals. |
Inclusion Criteria: * Adults with end stage renal disease who are receiving dialysis Exclusion Criteria: * Subjects with significant gastrointestinal disorders * Subjects who are pregnant or nursing * Subjects currently taking lanthanum carbonate, sevelamer hydrochloride, cinacalcet hydrochloride...